Ages ≤ 70 years, G1–2 tumor grade, interval from primary tumor surgery to liver metastases > 12 months, preoperative carcinoembryonic antigen (CEA) ≤ 200 ng/mL, more than one liver lesion, and high exosomal miRNA risk were the benefit factors for adjuvant chemotherapy (Figure 5A). The gene discussed is CEACAM5; the disease is neoplasm.